Qi-Guan JIN, Ming ZHOU, Yu-Long HU, Liang CHEN, Yu LIU, Yu-Qing WANG, Mei-Tong WU, Rui-Xue ZHANG, Wen-Ying LIU

Farelerde Subkutan Lewis Akciğer Kanseri Modelinde İstiridye Enzimatik Hidrolizatının Akciğer Metastazı Üzerine Önleyici Etkisi ve Mekanizması

İstiridye enzimatik hidrolizatının (OEH) Lewis akciğer kanserinin metastazı üzerine inhibitör etkisinin araştırılması ve inhibitör mekanizmanın aydınlatılması amacıyla subkutan Lewis akciğer kanseri modeline göre C57BL / 6J erkek farelerde 5 hafta boyunca OEH’in düşük (LOEH), orta (MOEH) ve yüksek (HOEH) dozlarının günlük gavajı uygulandı. Subkutan tümörün hacmi ve ağırlığı ölçüldü, akciğer metastatik nodüller sayıldı, tümör ilişkili makrofajlar (TAM; CD11b+F4/80+) sayıldı, deri altı tümör yapılarda E-kaderin, Vimentin, microRNA-21 ve microRNA-218 ekspresyonu ölçüldü. OEH’in MOEH ve HOEH sağaltım gruplarının subkutan tümör ağırlığını önemli ölçüde azalttığı (P=0.013, P=0.007) ve doza bağlı olarak akciğer metastazını önemli ölçüde engellediği (χ2=13.16, P=0.004) saptandı. E-kaderin ekspresyonu, yüksek dozda istatistiksel bir artış gösterirken, tüm OEH gruplarında Vimentin ekspresyonu ve subkutan tümördeki TAM hücre sayısında önemli ölçüde azalma saptandı (P

Inhibitory Eff ect and Mechanism of Oyster Enzymatic Hydrolysate on Lung Metastasis in the Subcutaneous Lewis Lung Cancer Model in Mice

In order to investigate the inhibitory eff ects of oyster enzymatic hydrolysate (OEH) on the metastasis of Lewis lung cancer and to evaluate itsmechanism, daily gavage of low(LOEH), medium(MOEH) and high (HOEH) doses of OEH for 5 weeks was administered based on the subcutaneousLewis lung cancer model in C57BL/6J male mice, the volume and weight of subcutaneous tumor were measured, the lung metastatic noduleswere counted, the number of tumor-associated-macrophages (TAMs; CD11b+F4/80+), the expression of E-cadherin, Vimentin, microRNA-21and microRNA-218 in subcutaneous tumor were measured. It was found that OEH treatment significantly decreased the subcutaneous tumorweight for the MOEH and HOEH groups (P=0.013, P=0.007) and significantly inhibited lung metastasis in a dose-dependent manner (χ2=13.16,P=0.004). The expression of E-cadherin showed a statistical increase at high dose, while the expression of Vimentin and the number of TAMs insubcutaneous tumor was significantly decreased at all OEH doses (P

PDF

___

1. Goldstraw P, Crowley J, Chansky K, Giroux DJ, Groome PA, Rami-Porta R, Postmus PE, Rusch V, Sobin L, International Association for the Study of Lung Cancer International Staging Committee, Participating Institutions: The IASLC lung cancer staging project: Proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol, 2 (8): 706-714, 2007. DOI: 10.1097/ JTO.0b013e31812f3c1a
2. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet‐Tieulent J, Jemal A: Global cancer statistics, 2012. CA Cancer J Clin, 65 (2): 87-108, 2015. DOI: 10.3322/ caac.21262
3. Nie LG: Screening for lung cancer‐Opportunities and challenges. Chin J Lung Cancer, 18 (12): 721-724, 2015. DOI: 10.3779/j.issn.1009-3419.2015.12.01
4. Herbst RS, Morgensztern D, Boshoff C: The biology and management of non-small cell lung cancer. Nature, 553, 446-454, 2018. DOI: 10.1038/ nature25183
5. Gu K, Li MM, Shen J, Liu F, Cao JY, Jin S, Yu Y: Interleukin-17-induced EMT promotes lung cancer cell migration and invasion via NF-κB/ZEB1 signal pathway. Am J Cancer Res, 5 (3): 1169-1179, 2015.
6. Lamouille S, Xu J, Derynck R: Molecular mechanisms of epithelialmesenchymal transition. Nat Rev Mol Cell Biol, 15, 178-196, 2014. DOI: 10.1038/ nrm3758
7. Galdiero MR, Garlanda C, Jaillon S, Marone G, Mantovani A: Tumor associated macrophages and neutrophils in tumor progression. J Cell Physiol, 228 (7): 1404-1412, 2013. DOI: 10.1002/jcp.24260
8. Chen J: Expression of miRNA-218 in non-small cell lung cancer and its relationship with prognosis. J Clin Pulm Med, 24 (6): 1102-1104, 2019. DOI: 10.3969/j.issn.1009-6663.2019.06.035
9. Luan L, Han B, Wang CF, Bai Y, Teng M, Huan DW, Xu HT, Wang EH: MiR- 218-1-3p expression in non-small cell lung cancer and its clinical significance. J China Med Univ, 43 (2): 181-183, 2014.
10. Zhang CL, Ge SL, Hu CL, Yang N, Zhang JR: MiRNA-218, a new regulator of HMGB1, suppresses cell migration and invasion in non-small cell lung cancer. Acta Biochim Biophys Sin, 45 (12): 1055-1061, 2013. DOI: 10.1093/abbs/gmt109
11. Liu ZL, Wang H, Liu J, Wang ZX: MicroRNA-21 (miR-21) expression promotes growth, metastasis, and chemo-or radioresistance in non-small cell lung cancer cells by targeting PTEN. Mol Cell Biochem, 372, 35-45, 2013. DOI: 10.1007/s11010-012-1443-3
12. Fang L, Ma HX, Li LH, Yang XQ, Rong H, Zhu CB: Analysis and evaluation of nutrient composition in Ostrea rivularis from south China sea coast. Sci Tech Food Indus, 39 (2): 301-307, 2018. DOI: 10.13386/j.issn1002-0306.2018.02.056
13. Fang L, Li GM, Xu SS, Lu L, Gu RZ, Cai MY, Lu J: Research progress of bioactive peptides from oyster. J Food Saf Qual, 9 (7): 1548-1553, 2018. DOI: 10.3969/j.issn.2095-0381.2018.07.015
14. Dai CM, Liao XY, Ye ZG: Review on chemical composition, pharmacological activity and application of Marine Traditional Chinese Medicine Oyster. Nat Prod Res Dev, 28(3): 471-474, 2016. DOI: 10.16333/j.1001-6880.2016.3.028
15. Feng L, Zhao WJ, Chang WZ: Research progress in the pharmacological action and clinical application of oyster. Inf Tradit Chin Med, 28 (1): 114-116, 2011.
16. Li CZ, Pan ZF, Chen YH, Zhang YQ, Huang XR, Huang JX: Research progress in active substance of oyster softbody. Sci Tech Food Indus, 33 (8): 412- 415, 2012. DOI: 10.13386/j.issn1002-0306.2012.08.105
17. Zhao XL: Study on the biological activity of oyster and its food development. Jiangsu Condiment and Subsidiary Food, 26 (4): 37-41, 2009. DOI: 10.16782/j.cnki.32-1235/ts.2009.04.013
18. Umayaparvathi S, Meenakshi S, Vimalraj V, Arumugam M, Sivagami G, Balasubramanian T: Antioxidant activity and anticancer effect of bioactive peptide from enzymatic hydrolysate of oyster (Saccostrea cucullata). Biomed Prev Nutr, 4 (3): 343-353, 2014. DOI: 10.1016/j.bionut.2014.04.006
19. Bertram JS, Janik P: Establishment of a cloned line of Lewis lung carcinoma cells adapted to cell culture. Cancer Lett, 11 (1): 63-73, 1980. DOI: 10.1016/0304-3835(80)90130-5
20. Zhu H, Kauffman ME, Trush MA, Jia ZQ, Li YR: A simple bioluminescence imaging method for studying cancer cell growth and metastasis after subcutaneous injection of Lewis lung carcinoma cells in syngeneic C57BL/6 mice. React Oxyg Species (Apex), 5 (14): 118-125, 2018. DOI: 10.20455/ ros.2018.813
21. Ma XM, Yu MW, Zhang GL, Yu J, Cao KX, Sun X, Yang GW, Wang XM: Comparison of mouse models of Lewis lung carcinoma subcutaneously transplanted at different sites. Acta Lab Anim Sci Sin, 25 (4): 386-390, 2017. DOI: 10.3969/j.issn.1005-4847.2017.04.008
22. National Research Council (US) Committee for the Update of the Guide for the Care and Use of Laboratory Animals: Guide for the Care and Use of Laboratory Animals. 8th ed., Washington (DC): National Academies Press (US), 2011. DOI: 10.17226/12910
23. Zhou LP, Ma K, Ma ZG, Bian J, Zhou H, Ji XE, Li SY: Effect of jian-pi-bu –shen-fang synergism chemotherapy on mice lewis lung cancer cells and its ultrastructure. J Ningxia Med Univ, 37 (7): 755-758, 2015. DOI: 10.16050/j.cnki. issn1674-6309.2015.07.008
24. Xu D, Lin F, Zhu XY, Liu WY, Chen XW, Feng JQ, Fan AQ, Cai MY, Xu YJ: Immunomodulatory effect of oyster peptide on immunosuppressed mice. J Peking Univ (Health Sci), 48 (3): 392-397, 2016. DOI: 10.3969 /j.issn.1671- 167X.2016.03.003
25. Tang M, Wang SM, Wei YL, Fu JT: Inhibition effects of Yuxiao San combined with cisplatin on transplanted tumor growths via upregulation of nm-23 and downregulation of K-ras in Lewis lung cancer mice. Oncol Lett, 17 (1): 1267-1273, 2019. DOI: 10.3892/ol.2018.9673
26. Zhou QQ, Zhang Z, Song LY, Huang CH, Cheng Q, Bi SX, Hu XJ, Yu RM: Cordyceps militaris fraction inhibits the invasion and metastasis of lung cancer cells through the protein kinase B/glycogen synthase kinase 3β/βcatenin signaling pathway. Oncol Lett, 16, 6930-6939, 2018. DOI: 10.3892/ol.2018.9518
27. Zhang JT, Qin XY, Jia FH, Yuan Y, Zhou M, Fang L, Zhang RX, Gu RZ, Liu WY: In vitro antioxidation and ACE inhibition of ovalbumin oligopeptides. Food Ferment Indus, 45 (12): 67-74, 2019. DOI: 10.13995/j.cnki.11-1802/ts.019561
28. Gu RZ, Liu WY, Lin F, Jin ZT, Chen L, Yi WX, Lu J, Cai MY: Antioxidant and angiotensin I-converting enzyme inhibitory properties of oligopeptides derived from black-bone silky fowl (Gallus gallus domesticus Brisson) muscle. Food Res Int, 49 (1): 326-333, 2012. DOI: 10.1016/j.foodres.2012.07.009
29. Wang ZF, Yang HY, Liu XB, Zhang RX, Liu SL: Effect of topotecan on survival and tumor metastasis of non-small cell lung cancer mouse models and its mechanism. Oncol Prog, 18 (1): 26-29,61, 2020.
30. Hsieh PF, Chueh PJ, Liu PF, Liao JW, Hsieh MK: Immune response evoked by tumor-associated NADH oxidase (tNOX) confers potential inhibitory effect on lung carcinoma in a mouse model. Am J Cancer Res, 9 (4): 740-751, 2019.
31. Shackelford C, Long G, Wolf J, Okerberg C, Herbert R: Qualitative and quantitative analysis of nonneoplastic lesions in toxicology studies. Toxicol Pathol, 30 (1): 93-96, 2002. DOI: 10.1080/01926230252824761
32. Chen YH, Li CZ, Li DR: The progress on biological activity and separation of the bioactive peptides of oyster protein. Food Res Dev, 36 (15): 135-138, 2015. DOI: 10.3969/j.issn.1005-6521.2015.15.033
33. Lundquist P, Artursson P: Oral absorption of peptides and nanoparticles across the human intestine: Opportunities, limitations and studies in human tissues. Adv Drug Deliv Rev, 106 (Pt B): 256-276, 2016. DOI: 10.1016/j.addr. 2016.07.007
34. Deng WY, Li N, Xia XX, Luo SX, Li SY: Status and progress of immunonutrition in tumour. J Chin Oncol, 20 (8): 619-624, 2014. DOI: 10.11735/ j.issn.1671-170X.2014.08.B002
35. Szefel J, Danielak A, Kruszewski WJ: Metabolic pathways of L-arginine and therapeutic consequences in tumors. Adv Med Sci, 64 (1): 104-110, 2019. DOI: 10.1016/j.advms.2018.08.018
36. Li QF, Huang DC, Shi SL, Liang Y, Li XQ: The regulation effects of bioactive peptides of oyster (BPO-L) on the cell cycle and gene expression of human lung adenocarcinoma A549 cells. J Xiamen Univ Nat Sci, 47 (1): 104–110, 2008. DOI: 10.3321/j.issn:0438-0479.2008.01.023
37. Liang Y, Huang DC, Shi SL, Li QF: Effects of oyster low molecular mass bioactive peptides on the morphology and ultrastucture of human lung adenocarcinoma A549 cells. J Xiamen Univ Nat Sci, 45 (z1): 177–180, 2006. DOI:10.3321/j.issn:0438-0479.2006.z1.044
38. Wu MT, Zhang HX, Zhang M, Bi Y, Xu HR, Ling K, Jin QG, Liu WY: Inhibition and mechanism of oyster enzymatic hydrolysate on Lewis lung cancer. Food Ferment Indus, 46 (11): 98-104, 111, 2020. DOI: 10.13995/j.cnki.11- 1802/ts.023063
39. Ma XP, Zhang H, Wang YP, Zhang L, MaJ, Peng T, Leng J: Downregulation of E-cadherin upregulates the phosphorylation level of GSK-3β in human hepatoma cells. Acta Univ Med Nanjing, 32 (7): 896-902, 2012.
40. Thiery JP, Acloque H, Huang RYJ, Nieto MA: Epithelial-mesenchymal transitions in development and disease. Cell, 139, 871-890, 2009. DOI: 10.1016/ j.cell.2009.11.007
41. Ko H, So Y, Jeon H, Jeong MH, Choi HK, Ryu SH, Lee SW, Yoon HG, Choi KC: TGF-β1-induced epithelial–mesenchymal transition and acetylation of Smad2 and Smad3 are negatively regulated by EGCG in human A549 lung cancer cells. Cancer Lett, 335 (1): 205-213, 2013. DOI: 10.1016/j.canlet. 2013.02.018
42. Zhu QS, Rosenblatt K, Huang KL, Lahat G, Brobey R, Bolshakov S, Nguyen T, Ding Z, Belousov R, Bill K, Luo X, Lazar A, Dicker A, Mills GB, Hung MC, Lev D: Vimentin is a novel AKT1 target mediating motility and invasion. Oncogene, 30, 457-470, 2011. DOI: 10.1038/onc.2010.421
43. Xia D, Li YM, Tan XN, Kuang C, Guo JS: Effects of Feifukang on the growth of tumor and expression of E-cadherin,vimentin, and TGF-β in mice with Lewis lung cancer. J Tradit Chin Med Univ Hunan, 35 (3): 30-33, 2015. DOI: 10.3969/j. issn.1674-070X.2015.03.009.030.04
44. Chanmee T, Ontong P, Konno K, Itano N: Tumor-associated macrophages as major players in the tumor microenvironment. Cancers, 6 (3): 1670-1690, 2014. DOI: 10.3390/cancers6031670
45. Mantovani A, Allavena P: The interaction of anticancer therapies with tumor-associated macrophages. J Exp Med, 212 (4): 435-445, 2015. DOI: 10.1084/jem.20150295
46. Munn DH, Bronte V: Immune suppressive mechanisms in the tumor microenvironment. Curr Opin Immunol, 39, 1-6, 2016. DOI: 10.1016/j.coi. 2015.10.009
47. Noy R, Pollard JW: Tumor-associated macrophages: From mechanisms to therapy. Immunity, 41 (1): 49-61, 2014. DOI: 10.1016/j.immuni.2014.06.010
48. Ostuni R, Kratochvill F, Murray PJ, Natoli G: Macrophages and cancer: From mechanisms to therapeutic implications. Trends Immunol, 36 (4): 229- 239, 2015. DOI: 10.1016/j.it.2015.02.004
49. Davalos V, Esteller M: MicroRNAs and cancer epigenetics: A macrorevolution. Curr Opin Oncol, 22 (1): 35-45, 2010. DOI: 10.1097/CCO.0b013e328333dcbb
50. Kiran C, Deepika P: Lung cancer: microRNA and target database. Chin J Lung Cancer, 15 (7): 429-434, 2012. DOI: 10.3779/j.issn.1009-3419.2012.08.11
51. Davidson MR, Larsen JE, Yang IA, Hayward NK, Clarke BE, Duhig EE, Passmore LH, Bowman RV, Fong KM: MicroRNA-218 is deleted and downregulated in lung squamous cell carcinoma. PLoS One, 5 (9): e12560, 2010. DOI: 10.1371/journal.pone.0012560
52. Wu DW, Cheng YW, Wang J, Chen CY, Lee H: Paxillin predicts survival and relapse in non-small cell lung cancer by microRNA-218 targeting. Cancer Res, 70 (24): 10392-10401, 2010. DOI: 10.1158/0008-5472.CAN-10-2341
53. Chen P, Zhao YL, Li YJ: MiR-218 inhibits migration and invasion of lung cancer cell by regulating Robo1 expression. Chin J Lung Cancer, 20 (7): 452-458, 2017. DOI: 10.3779/j.issn.1009-3419.2017.07.03
54. Gong XW, Zheng LM, Sheng DQ, Zhang LH: Research progress of miR- 21 in non-small cell lung cancer. Chin Bull Life Sci, 30 (7): 765-770, 2018. DOI: 10.13376/j.cbls/2018091
55. Zhang XB, Peng F: Expression of microRNA-21 in peripheral blood and cancer tissues of patients with non-small cell lung cancer and its mechanism of involvement in tumor inhibition by regulating PTEN protein. Chin J Gerontol, 37 (22): 5571-5573, 2017.
56. Wang Y, Li JY, Tong LP, Zhang JW, Zhai AX, Xu K, Wei L, Chu M: The prognostic value of miR-21 and miR-155 in non-small-cell lung cancer: A metaanalysis. Jpn J Clin Oncol, 43 (8): 813-820, 2013. DOI: 10.1093/jjco/hyt084
57. Si ML, Zhu S, Wu H, Lu Z, Wu F, Mo YY: miR-21-mediated tumor growth. Oncogene, 26, 2799-2803, 2007. DOI: 10.1038/sj.onc.1210083
58. Wang XC, Wang W, Zhang ZB, Zhao J, Tan XG, Luo JC: Overexpression of miRNA-21 promotes radiation-resistance of non-small cell lung cancer. Radiat Oncol, 8:146, 2013. DOI: 10.1186/1748-717X-8-146